Acquisition of BSV to aid future growth of Mankind Pharma: V-C Juneja

The acquisition of Bharat Serums and Vaccines would add a lot of value, aiding future growth of Mankind Pharma, according to Vice Chairman and Managing Director Rajeev Juneja.

On July 25, Mankind had announced that it will fully acquire Bharat Serums and Vaccines (BSV) from Advent International for an enterprise value of around Rs 13,630 crore.

"One thing should be very clear, this acquisition is not to really add some kind of revenue, but to add a lot of value, future growth, entry barrier, super specialty business in Mankind," Juneja said in an analyst call.

Whatever the company is paying for BSV, it is very relevant as the company has "so much of value" with well established business, he said.

The acquisition is in line with the company's strategy of buying high entry barrier businesses, he stated.

The buyout will solidify Mankind's position with complementary drug portfolio and extensive reach to target rapidly growing highly under-penetrated markets, especially in fertility,